达仁堂: 达仁堂2025年半年度业绩预告

Performance Forecast - The company expects a net profit attributable to shareholders of 1.84 billion to 2 billion yuan for the first half of 2025, representing an increase of 1.18228 billion to 1.34228 billion yuan compared to the same period last year, which is a year-on-year increase of 180% to 204% [2][4] - The expected net profit excluding non-recurring gains and losses is projected to be 560 million to 620 million yuan, which is a decrease of 73.83 million to 13.83 million yuan compared to the same period last year, reflecting a year-on-year decrease of 12% to 2% [3][4] Previous Year Performance - In the same period last year, the total profit was 747.6489 million yuan, and the net profit attributable to shareholders was 657.7193 million yuan, with a net profit excluding non-recurring gains and losses of 633.8312 million yuan [3] Reasons for Performance Increase - The significant increase in net profit is primarily due to the sale of a 12% stake in the joint venture Tianjin SmithKline Beecham Pharmaceuticals Co., Ltd. to Helion (China) Co., Ltd. and Haleon CH SARL, resulting in a disposal gain of 1.54 billion yuan. The company will not recognize investment income from this joint venture in the current period, which previously contributed 110 million yuan to investment income [3][4]